Premium
On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
Author(s) -
Hård AnnaLena,
Hellström Ann
Publication year - 2011
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2011.02445.x
Subject(s) - medicine , bevacizumab , pharmacokinetics , adverse effect , retinopathy of prematurity , vegf receptors , pharmacology , vascular endothelial growth factor , chemotherapy , pregnancy , biology , genetics , gestational age
Off‐label intravitreal use of the vascular endothelial growth factor (VEGF) antibody bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has been considered negligible. A literature search was performed with emphasis on potential adverse systemic effects in developing individuals. Conclusion: Intravitreal bevacizumab enters the general circulation, suppresses plasma VEGF levels and remains in the blood for more than 8 weeks in primates. Possible adverse effects on VEGF‐dependent development must be considered.